Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.
You may also be interested in...
Johnson & Johnson To Co-Promote Cephalon's ADHD Treatment Modafinil
Deal allows J&J to opt out if its own attention deficit/hyperactivity disorder therapy Concerta loses exclusivity.
Johnson & Johnson To Co-Promote Cephalon's ADHD Treatment Modafinil
Deal allows J&J to opt out if its own attention deficit/hyperactivity disorder therapy Concerta loses exclusivity.
Cephalon Expects To Reduce Modafinil Price For ADHD By About 40%
The company says it will price modafinil for attention deficit/hyperactivity disorder in-line with other branded products on the market at the time of launch. Based on current prices, Cephalon expects to reduce modafinil's price for ADHD to $3-$3.50 from the current $6 per pill price for Provigil.